This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Book Review

Clinical Manual of Drug Interaction: Principles for Medical Practice

David L. Dunner, MD

Published: July 15, 2010

Clinical Manual of Drug Interaction: Principles for Medical Practice

by Gary H. Wynn, MD; Jessica R. Oesterheld, MD; Kelly L. Cozza, MD; and Scott C. Armstrong, MD. American Psychiatric Publishing, Inc, Arlington, VA, 2009, 594 pages, $59.00 (paper).

Drug interactions are a very important consideration in clinical practice. This volume is divided into 4 sections: Basic Pharmacology, P450 Enzymes, Drug Interactions by Medical Specialty (includes gynecology, internal medicine, infectious diseases, neurology, oncology, pain management, psychiatry, and transplant surgery/rheumatology), and Practical Matters (includes medicolegal implications and how to retrieve and review the literature). It is a multiauthored text and reasonably up-to-date (chapters for a 2009 publication are generally written in 2008). The material is well presented, and there are illuminating case reports. The referencing is excellent, and the index is useful. The issue of P-glycoproteins is well covered.

I read the introduction, the section on P450 enzymes, the section on drug interactions in psychiatry, and the last section. The material was presented in a concise manner, and I learned some facts that would likely be useful for me in my clinical practice.

However, I came away with the concern that use of a textbook on this material is not sufficient to keep current with drug interactions as compared with Internet use. This book has great value more as a basic primer of drug interactions than as a text to review the potential for a drug interaction regarding a medication you wish to prescribe.

David L. Dunner, MD

Author affiliation: University of Washington School of Medicine, Seattle. Potential conflicts of interest: In the past year, Dr Dunner has received grant support from Cyberonics and Neuronetics (owns a Neurostar device to treat patients with rTMS); has been a consultant/advisory board member for Eli Lilly, Wyeth, and Sanofi Aventis; and has been on the speakers bureaus of Pfizer, Wyeth, Neuronetics, AstraZeneca, and Janssen.

Volume: 71

Quick Links: